Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

Bin Li   ¹ , PhD ;   Steven A Eschrich   ² , PhD ;   Anders Berglund   ² , PhD ;   Melissa Mitchell   ³ , BA ;   David Fenstermacher   ⁴ , PhD ;   Hadi Danaee   ⁵ , SD ;   Hongyue Dai   ⁶ , PhD ;   Daniel Sullivan   ⁷ , MD ;   William L Trepicchio   ⁵ , PhD ;   William S Dalton   ³ , MD

¹ Takeda Pharmaceuticals International Company, Takeda Data Science Institute, Cambridge, MA, United States

² H Lee Moffitt Cancer Center and Research Institute, Biostatistics and Bioinformatics, Tampa, FL, United States

³ M2Gen, Administration, Tampa, FL, United States

⁴ MedImmune, LLC, Research Bioinformatics, Gaithersburg, MD, United States

⁵ Takeda Pharmaceuticals International Company, Translational and Biomarker Research, Cambridge, MA, United States

⁶ M2Gen, Bioinformatics, Tampa, FL, United States

⁷ H Lee Moffitt Cancer Center and Research Institute, Blood and Marrow Transplantation, Tampa, FL, United States